We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

KBR:NYSEKBR, Inc. Analysis

Data as of 2026-06-13 - not real-time

$35.84

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

KBR is trading at $35.84, which is above the 20‑day SMA of 34.14 and just below the 50‑day SMA of 35.11, signaling short‑term weakness. The RSI of 56.5 shows neutral momentum while the MACD line (0.27) sits above its signal (0.05), producing a positive histogram and a bullish signal. The price is near the resistance level of $36.68 and well above the support at $29.94, limiting immediate upside. High 30‑day volatility (46.9%) combined with a decreasing volume trend raises short‑term risk, although a low beta of 0.45 suggests limited market‑wide sensitivity.
Fundamentally, the trailing P/E of 10.6 is far below the industry average of 30.6, yet the DCF‑derived fair value of $7.06 indicates the stock is heavily overvalued at current levels. Revenue fell 4.7% YoY, but margins are modestly expanding and free cash flow of $250 M supports a 1.84% dividend with a 19% payout ratio, implying dividend sustainability. However, a debt‑to‑equity ratio of 176% introduces leverage risk. The blend of modest growth, solid cash generation, and significant overvaluation leads to a cautious outlook.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 7/10

Key Factors

  • Price near resistance with limited upside
  • Overvaluation relative to DCF fair value
  • Decreasing volume and high short‑term volatility

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Solid cash generation and sustainable dividend
  • Revenue decline and high leverage
  • Neutral technical momentum (RSI, MACD) indicating range‑bound behavior

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • Stable government contract exposure
  • Potential for margin expansion and decarbonization opportunities
  • Continued overvaluation limiting upside despite value metrics

Key Metrics & Analysis

Financial Health

Revenue Growth-4.70%
Profit Margin5.21%
P/E Ratio10.6
ROE29.15%
ROA4.98%
Debt/Equity176.90
P/B Ratio2.9
Op. Cash Flow$534.0M
Free Cash Flow$250.4M
Industry P/E30.6

Technical Analysis

TrendBearish
RSI56.6
Support$29.94
Resistance$36.68
MA 20$34.14
MA 50$35.11
MA 200$41.10
MACDBullish
VolumeDecreasing
Fear & Greed Index89.86

Valuation

Fair Value$7.06
Target Price$46.57
Upside/Downside29.94%
GradeOvervalued
TypeValue
Dividend Yield1.84%

Risk Assessment

Beta0.80
Volatility46.87%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.